FDA puts hold on GenVec TNFerade
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GenVec's gene-based oncologicTNFerade is on clinical hold after a possible increased risk of blood clots is seen in interim results of a Phase II esophageal cancer study. In the 24-patient trial, three of eight patients receiving the highest dose developed pulmonary embolism, one of whom died. Investigators judged the death "possibly related to TNFerade and underlying disease." The interim data were presented Oct. 1 at the European Organization for Research & Treatment of Cancer meeting in Geneva, Switzerland. GenVec plans to provide FDA with additional data, the firm said Oct. 7. In addition to esophageal cancer, GenVec's Phase II TNFerade program is looking at locally advanced pancreatic and rectal cancers...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.